Preoperative sintilimab with chemoradiotherapy boosted pathological complete response rates in patients with resectable, locally advanced esophageal squamous cell carcinoma.
Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing results for treatment decision-making.
Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic stem cell transplantation.
The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus chemotherapy between early and late responders with ESCC.
Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.
SHR-1701 plus CAPOX chemotherapy reduced treatment delays and dose reductions compared with placebo plus CAPOX in HER2-negative gastric/GEJ cancer.
Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.
Oncology nurses can provide patients with information regarding the risks and benefits of these medications in cancer treatment.
Everolimus plus lanreotide resulted in a progression-free survival of 29.7 months in patients with gastroenteropancreatic neuroendocrine tumors, compared with 11.5 months with everolimus monotherapy.
Combining aerobic and resistance-based physical activity with dexamethasone may improve quality of life and reduce the effects of fatigue.
Pembrolizumab, added to preoperative radiation and surgery, prolonged disease-free survival in patients with soft tissue sarcoma of the extremity.
Patients receiving ponsegromab experienced significantly greater weight gain and physical activity than those receiving placebo.
Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.
Significant improvements in skin toxicity were observed by week 6 in all patients treated with HT-001 in the phase 2a CLEER-001 trial.
Device programming encounters near the end of life occurred in nearly half of patients with ICDs, offering a potential opportunity for goals-of-care discussions.
The FELIX trial demonstrated that obe-cel induced durable remissions in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Datopotamab deruxtecan-dlnk received approval from the FDA for previously treated unresectable or metastatic, HR-positive, HER2-negative breast cancer.
The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to confirm this finding.
Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.
The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) whose disease progressed after chemotherapy.
The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous stem cell transplant.
Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized starting doses, may improve patient outcomes.
MaaT013 showed positive results in the phase 3 ARES trial, meeting its primary endpoint of GI-ORR at day 28 in patients with third-line GI-aGVHD.
Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion center.
GSK5764227 has been granted FDA breakthrough therapy designation, potentially expediting its development as a treatment for relapsed/refractory osteosarcoma.
NCCN guidelines now recommend ctDNA testing for MRD assessment for patients with PET-positive DLBCL after treatment.
Frontline treatment with belzutifan and cabozantinib resulted in durable responses and a manageable safety profile in patients with previously untreated advanced ccRCC.
Sasanlimab plus BCG improved outcomes in high-risk, BCG-naive non-muscle-invasive bladder cancer.
An APP’s research is focused on chemo-induced peripheral neuropathy in Black breast cancer survivors and its impact on their long-term quality of life.
The FDA has released draft guidance with recommendations on tissue biopsies in clinical trials for adults and children.
